EDS

Nurse Well-Being the Focus of Engage, Powered By ENA-Golisano Children's Hospital Partnership

Retrieved on: 
tisdag, april 23, 2024

SCHAUMBURG, Ill., April 23, 2024 /PRNewswire/ -- Engage, Powered by ENA, on Tuesday announced a new partnership with Golisano Children's Hospital of Southwest Florida's emergency department that centers on enhancing the well-being and professional growth of emergency nurses who play an integral role in the care of pediatric patients.

Key Points: 
  • Engage, a subsidiary of the Emergency Nurses Association, launched in 2023 with a mission to elevate emergency nursing excellence through healthy and safe workplaces.
  • To accomplish that, Engage partnered with 25 EDs across the country, including Golisano, during its first year.
  • "Engage's goal is to empower these dedicated professionals by providing them with the resources and support they need to excel in pediatric emergency care."
  • "We aim to ensure our nurses feel valued, heard and supported so they can excel in their roles," Callender added.

Emergency Department Nurses Take To Capitol Hill

Retrieved on: 
onsdag, april 17, 2024

WASHINGTON, April 17, 2024 /PRNewswire/ -- Emergency nurses are strong advocates for the laws and tools they need to be safe at work and sufficiently prepared to care for all their patients. Emergency nurses from nearly every state gathered in Washington, D.C., this week for the Emergency Nurses Association's annual Day on the Hill advocacy event.

Key Points: 
  • Emergency nurses from nearly every state gathered in Washington, D.C., this week for the Emergency Nurses Association's annual Day on the Hill advocacy event.
  • 3765) is an ENA priority this year because of its importance as the only federal program dedicated to improving emergency care for children.
  • ENA also continues to be a leading voice for legislation aimed at reducing the frequency and severity of workplace violence against emergency nurses.
  • "We know workplace violence is a problem in the emergency department but many times it goes unreported.

Public Safety Solutions Summit Leaves Lasting Impact

Retrieved on: 
måndag, april 15, 2024

SHELTON, Conn., April 15, 2024 /PRNewswire/ -- With two successful Public Safety Solutions Summits under its belt, Extra Duty Solutions (EDS) once again brought together law enforcement decision-makers from across the region at their third annual Summit on April 3-4, 2024, at the Grandover Resort in Greensboro, NC.

Key Points: 
  • SHELTON, Conn., April 15, 2024 /PRNewswire/ -- With two successful Public Safety Solutions Summits under its belt, Extra Duty Solutions (EDS) once again brought together law enforcement decision-makers from across the region at their third annual Summit on April 3-4, 2024, at the Grandover Resort in Greensboro, NC.
  • The Summit was limited to 50 participants, ensuring that the setting would be conducive to personal interactions and discussions.
  • The Summit opened with welcome remarks from retired Greensboro, NC Chief of Police and EDS Vice President of Business Development Wayne Scott.
  • "Seeing such a high level of engagement from the attendees only reaffirms our commitment to providing educational opportunities to public safety leaders," said CEO Rich Milliman.

Economic Bulletin Issue 3, 2024

Retrieved on: 
torsdag, april 25, 2024

The European Banking Authority (EBA) today launched a public consultation on its draft Regulatory Technical Standards (RTS) on the method for identifying the main risk driver and determining whether a transaction represents a long or a short position. These RTS are part of the Phase 1 deliverables of the EBA roadmap on the implementation of the EU banking package in the area of market risk. The consultation runs until 24 July 2024.

Key Points: 


The European Banking Authority (EBA) today launched a public consultation on its draft Regulatory Technical Standards (RTS) on the method for identifying the main risk driver and determining whether a transaction represents a long or a short position. These RTS are part of the Phase 1 deliverables of the EBA roadmap on the implementation of the EU banking package in the area of market risk. The consultation runs until 24 July 2024.

Christine Lagarde: Unlocking the power of ideas

Retrieved on: 
tisdag, april 23, 2024

Since 2022 rising housing costs have, on average, largely been offset by growth in household income, leading to stable housing cost to household income ratios.

Key Points: 
  • Since 2022 rising housing costs have, on average, largely been offset by growth in household income, leading to stable housing cost to household income ratios.
  • The housing cost burden has, however, increased slightly for both renter and mortgage households at the upper end of the income distribution.

A new measure of firm-level competition: an application to euro area banks

Retrieved on: 
torsdag, april 18, 2024

Abstract

Key Points: 
    • Abstract
      This paper extends Boone (2008) by introducing a competition measure at the individual
      firm level rather than for an entire market segment.
    • We apply this extended Boone indicator to individual bank-level competition
      in the loan market in the four largest euro area countries and Austria.
    • Our new measure of firm-level competition enriches and complements
      other competition measures and provides a promising starting point for future market
      power analyses.
    • The only measure among non-structural measures that is based on the
      concept of competition as a process of rivalry is the Boone (2008) indicator.
    • We introduce
      a new performance measure of competition by extending the Boone indicator to the
      individual firm level.
    • Introduction
      The ability to reliably measure competition is valuable to researchers, analysts, and
      policymakers, especially antitrust authorities, financial supervisors, and central banks.
    • One broad
      category of indicators often used to measure competition are structural competition
      measures, such as static concentration measures, and dynamic measures, e.g., entry and
      exit rates.
    • Out of these measures, the only measure based on the
      concept of competition as a process of rivalry is the Boone indicator.
    • This study introduces a new performance measure of competition by extending the
      Boone indicator to the individual firm level.
    • It thus measures the
      increase in profits in percent of one percentage point increase in efficiency, with marginal
      costs as measure of efficiency.
    • We extend the theoretical
      underpinning of the measurement of competition for the entire market of Boone (2008) by
      a new measure of individual firm-level competition.
    • A concern of the literature is the gap
      between the practical application and the theoretical framework of Boone (2008).
    • We introduce within the same theoretical
      framework a new measure of competition on firm level, the MRP.
    • Our new
      measure significantly augments the antitrust evaluative framework by shedding light on
      whether a merger results in a less competitive market.
    • Our novel indicator focuses on
      firms? incentives to enhance their relative efficiency, as manifested in the elasticity
      between relative profits and efficiency.
    • However, an inefficient firm that is foreclosed could be more
      competitive than the larger efficient firm that relies on its scale economies.
    • Our new metric of competition unveils
      banks? ability to influence their profitability in the short term by cutting costs relative to
      their peers.
    • The new MRP indicator provides the ability to assess the impact
      of individual banks? competitiveness on their interest rate-setting behaviour in loan
      markets.
    • Incorporating this information promises a more refined understanding of the impact and
      timing of monetary policy rates changes on the real economy.
    • Section 3 introduces within the Boone
      (2008) theoretical framework our new measure of individual firm-level competition,
      including the interpretation of the MRP.
    • Section 4 provides an application of our new
      ECB Working Paper Series No 2925

      6

      individual firm-level competition measure to the loan market.

    • The StructureConduct-Performance paradigm (SCP) provides a traditional framework in the field of
      industrial organization for analysing competition behaviour in markets.
    • Concentrated
      markets ease the possibilities to collude implicitly or explicitly and therefore concentrated
      markets result in higher prices and profits.
    • For example, a tougher competition
      setup may lead to a reallocation of market shares, potentially forcing some firms to exit
      the market.
    • This approach gives firms? strategic behaviour
      central stage and focuses on the strategic interaction on prices and quantities, known as
      conjectural variation.
    • Another measure from
      this strand of literature is the H-statistic developed by Panzar and Rosse (1987).
    • The only competition measure from this performance literature where competition is the
      outcome from a process of rivalry is the Boone indicator.
    • A continuous and monotonically increasing relationship exists between
      RPD and the level of competition if firms are ranked by decreasing efficiency.
    • (2013) compare the Boone indicator with the price-cost margin
      and conclude that the profit elasticity is a more reliable measure of competition.
    • The high
      elasticity of profits to efficiency unequivocally indicates that the high market shares and
      therefore high profits are due to high efficiency.
    • A firm that quickly passes changes to the input prices is seen as a price
      taker with little market power.
    • Indicators of competition tend to measure different phenomenon and may provide
      conflicting messages, as reported for European banking by Carbo et al.
    • Application 2: Test the ?quiet life? and related market structure hypotheses using the
      MRP as competition or market structure measure.
    • Data
      Our application to individual bank-level competition in the euro area loan market uses
      balance sheet and income statement data from the Moody?s Analytics BankFocus for the
      calendar years 2013-2020.
    • As such, most publications
      on competition in the euro area includes the largest four member states.
    • Due to these restrictions the database was reduced to an unbalanced panel of up to 1862
      banks (depending on the year) from five euro area countries.
    • Application 1: Measure bank competition using MRP
      Looking at the distribution of the MRP for individual banks (Fig.
    • A similar finding for the four largest euro area countries as a group is
      reported in Carbo et al.
    • Application 2: Test of market structure hypotheses using MRP
      Our new measure of individual-bank competition can be used to test market structure
      theories.
    • Euro area banks? market power,
      lending channel and stability: the effects of negative policy rates, European Central Bank
      Working Paper, 2790 (February).
    • A
      new approach to measuring competition in the loan markets of the euro area, Applied
      Economics, 43 (23), 3155?3167.
    • Impact of bank competition on the interest rate pass-through in the euro area, Applied
      Economics, 45 (11), 1359?1380.

EQS-News: Daldrup & Söhne AG welcomes BMWK and KfW initiative on insurance solutions for deep boreholes

Retrieved on: 
onsdag, april 10, 2024

Oberhaching / Ascheberg, 25 March 2024 - Daldrup & Söhne AG (ISIN DE0007830572), drilling technology and geothermal specialist, supports the initiative of the Federal Ministry of Economics and Technology (BMWK) and the KfW development bank to establish a state-supported insurance solution for the so-called exploration risk for deep geothermal wells.

Key Points: 
  • Oberhaching / Ascheberg, 25 March 2024 - Daldrup & Söhne AG (ISIN DE0007830572), drilling technology and geothermal specialist, supports the initiative of the Federal Ministry of Economics and Technology (BMWK) and the KfW development bank to establish a state-supported insurance solution for the so-called exploration risk for deep geothermal wells.
  • KfW loans can already be applied for the realisation of deep geothermal projects, but the securing of the discovery has not yet been included.
  • Andreas Tönies, CEO of Daldrup & Söhne AG, welcomes the BMWK's plans to insure exploration risks: "A state-backed insurance solution will remove a major hurdle for municipal and private clients of deep geothermal projects.
  • Together with well-known partners in the insurance industry, Daldrup & Söhne AG has developed a concept to cover exploration risks during the construction of deep geothermal projects.

CIO Leadership: Celebrating Charlie Feld and Other Recipients of HMG Strategy’s Global Leadership Institute Awards at the 15th Annual Dallas C-Level Technology Leadership Summit on April 2

Retrieved on: 
torsdag, mars 28, 2024

“In 2024, our recognition program will honor elite global technology, business and search leaders whose teams are delivering unparalleled value to their organizations.

Key Points: 
  • “In 2024, our recognition program will honor elite global technology, business and search leaders whose teams are delivering unparalleled value to their organizations.
  • For more information about the 15th Annual C-Level Dallas Technology Leadership Summit and to register, click here .
  • HMG Strategy is also excited to be hosting its 13 th Annual Washington, D.C. C-Level Technology Leadership Summit on April 18 at the Ronald Reagan Building.
  • To learn more about the 13th Annual Washington, D.C. C-Level Technology Leadership Summit and to register for the event, click here .

Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

Retrieved on: 
tisdag, mars 26, 2024

CELEBRATION, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced top-line data from its placebo-controlled, double-blind Phase 2 clinical trial (NCT05668754) evaluating the safety and tolerability of KP1077 (serdexmethylphenidate, or SDX) in patients with idiopathic hypersomnia (IH). This proof-of-concept study was not powered to demonstrate statistical significance.   The data gathered for several secondary and exploratory endpoints, including the Epworth Sleepiness Scale (ESS), Idiopathic Hypersomnia Severity Scale (IHSS) and Sleep Inertia Visual Analog Scale (SIVAS) will inform the Phase 3 study design.

Key Points: 
  • CELEBRATION, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced top-line data from its placebo-controlled, double-blind Phase 2 clinical trial ( NCT05668754 ) evaluating the safety and tolerability of KP1077 (serdexmethylphenidate, or SDX) in patients with idiopathic hypersomnia (IH).
  • The data gathered for several secondary and exploratory endpoints, including the Epworth Sleepiness Scale (ESS), Idiopathic Hypersomnia Severity Scale (IHSS) and Sleep Inertia Visual Analog Scale (SIVAS) will inform the Phase 3 study design.
  • The results from the completed Phase 2 trial provide key information for the design of a potentially pivotal Phase 3 trial of KP1077 in patients with IH.
  • The Company plans to request an end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration to seek guidance on the Phase 3 clinical trial design.

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy

Retrieved on: 
måndag, mars 25, 2024

AXS-12 also reduced excessive daytime sleepiness (EDS) severity, improved cognitive function, and reduced overall narcolepsy severity as compared to placebo.

Key Points: 
  • AXS-12 also reduced excessive daytime sleepiness (EDS) severity, improved cognitive function, and reduced overall narcolepsy severity as compared to placebo.
  • SYMPHONY was a Phase 3 multicenter, randomized, double-blind, placebo-controlled trial in which 90 patients with a diagnosis of narcolepsy with cataplexy were randomized to treatment with AXS-12 or placebo for 5 weeks.
  • “The SYMPHONY Phase 3 trial results confirm the promise and potential of AXS-12 for the treatment of narcolepsy,” said Dr. Herriot Tabuteau, CEO of Axsome Therapeutics.
  • Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss the topline SYMPHONY study results in narcolepsy.